Preparation and evaluation of 68Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors

Journal of Nuclear Medicine

Volumn 46, Issue 11, 2005, Pages 1881-1888

  Velikyan, Irina ^a,b   Sundberg, Åsa Liljegren ^c   Lindhe, Örjan ^b   Höglund, A Urban ^b   Eriksson, Olof ^b   Werner, Eva ^b   Carlsson, Jorgen ^c   Bergström, Mats ^b   Långström, Bengt ^a,b,d   Tolmachev, Vladimir ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Uppsala Imanet AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Uppsala Imanet   (Sweden)

Author keywords

68Ga; Epidermal growth factor; Malignant tumors; MicroPET; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; GALLIUM 68; 68GA DOTA HEGF; 68GA-DOTA-HEGF; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; IMAGING SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; DRUG SCREENING; EVALUATION; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 33644818017     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
2. Collins VP. Amplified genes in human gliomas. Semin Cancer Biol. 1993;4:27-32.
3. Bigner SH, Burger PC, Wong AJ, et al. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol. 1988; 47:191-205.
4. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999;53: 167-176.
5. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003; 200:290-297.
6. Hirsch ER, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21: 3798-3807.
7. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGER targeting. Ann Oncol. 2004;15:1007-1012.
8. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res. 2002;8:3454-3460.
9. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28-32.
10. Dadparvar S, Krishna L, Miyamoto C, et al. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer. 1994;73:884-889.
11. 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun. 2002;23:1155-1164.
12. 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med. 2004;45:1683-1687.
13. Blomquist E, Carlsson J. Strategy for planned radiotherapy of malignant gliomas: postoperative treatment with combinations of high-dose proton irradiation and tumor seeking radionuclides. Int J Radiat Oncol 1992;22:259-263.
14. 131I- labeled epidermal growth factor. Clin Cancer Res. 1996;2:13-20.
15. 111In-labeled epidermal growth factor (EGE) bound to cultured A431 tumor cells. Nucl Med Biol. 2000;27:827-835.
16. Reilly RM, Gariepy J. Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical. J Nucl Med. 1998;39:1036-1043.
17. 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjug Chem. 1997;8:289-295.
18. 99mTc]HYNIC-hEGE, a potential agent for imaging of EGE receptors in vivo: preparation and pre-clmical evaluation. Oncol Rep. 2005;13:1169-1175.
19. Hnatowich DJ, Qu T, Chang E, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med. 1998;39:56-64.
20. 111In]Bz-DTPA-hEGF: preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. Cancer Biother Radiopharm. 2003;18:643-654.
21. Lundqvist H, Lubberink M, Tolmachev V. Positron emission tomography. Eur J Phys. 1999;19:537-552.
22. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers. 2002;66:381-392.
23. 68Ga-Labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
24. 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-560.
25. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Research Foundation Workshop. 2005:43-72.
26. Velikyan I, Lendvai G, Valila M, et al. Microwave accelerated Ga-68-labelling of oligonucleotides. J Labelled Compds Radiopharm. 2004;47:79-89.
27. Lavén M, Velikyan I, Djodjic M, et al. Imaging of peptide adsorption to microfluidic channels in a plastic compact disc using a positron emitting radionuclide. Lab on a Chip. 2005;5:756-763.
28. Westermark B, Magnusson A, Heldin CH. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res. 1982;8:491-507.
29. Elander N, Jones JR, Lu SY, Stone-Elander S. Microwave-enhanced radiochemistry. Chem Soc Rev. 2000;29:239-249.
30. 177Lu]Bz-DTPA-EGF: preclinical characterization of a potential radionuclide targeting agent against glioma. Cancer Biother Radiopharm. 2004;19:195-204.
31. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
32. 111In]Bz-DTPA-hEGF in normal mice. Cancer Biother Radiopharm. 2004;19: 491-501.
33. Dubey S, Schiller JH. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist. 2005;10:282-291.
34. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology. 2000;141:3304-3312.
35. 3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693-698.
36. 111In-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol. 2003; 30:253-260.